StreetAlpha.app
Home › Stocks › ZLAB

Zai Lab Ltd (ZLAB)

Healthcare
$21.03
▼ −4.06%
LAST CLOSE · NOV 20

Zai Lab is a Shanghai-based biopharmaceutical company that sells prescription medicines for cancer, autoimmune and infectious diseases. It last closed at $21.03 on Nov 20, down 4.06% on the day. The next earnings report for ZLAB is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, ZLAB reported EPS of -$0.04 on revenue of $108.2M, with revenue down 6.8% from a year ago. Over its last 8 reports the stock moved an average of 5.7% the session after earnings. Over the last 12 months ZLAB insiders bought $99K of stock on the open market and sold $11.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is ZLAB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ZLAB.

Key Stats

Last 12 months
Results
Revenue
$441.7M
+0.0% vs a year ago
Net income
−$198.4M
−44.9% margin
EPS (diluted)
−$0.18
Free cash flow
−$163.3M
−37.0% margin
Balance sheet
Cash & equivalents
$549.7M
At Sep 30
Shareholder equity
$563.3M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $144.3M$144.3MFY2021FY2022: $215.0M$215.0MFY2022FY2023: $266.7M$266.7MFY2023FY2024: $399.0M$399.0MFY2024FY2025: $460.2M$460.2MFY2025

From ZLAB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
-$0.04
Quarter ended Sep 2026
Year ago EPS
-$0.03
Same quarter last year
Revenue
$108.2M
−6.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.08Dec '24Mar 2025: -$0.04Mar '25Jun 2025: -$0.04Jun '25Sep 2025: -$0.03Sep '25Dec 2025: -$0.05Dec '25Mar 2026: -$0.05Mar '26Jun 2026: -$0.05Jun '26Sep 2026: -$0.04Sep '26Latest -$0.04
Revenue by quarter
Dec 2024: $109.1MDec '24Mar 2025: $106.5MMar '25Jun 2025: $110.0MJun '25Sep 2025: $116.1MSep '25Dec 2025: $127.6MDec '25Mar 2026: $99.6MMar '26Jun 2026: $106.3MJun '26Sep 2026: $108.2MSep '26Latest $108.2M
How ZLAB moved after its last 8 reports
Average move the session after a report ±5.7%
Nov 5, 2026Time not announced−0.9%
Aug 6, 2026Time not announced+13.7%
May 7, 2026Time not announced−5.9%
Feb 26, 2026Time not announced+1.6%
Nov 6, 2025Time not announced−6.7%
Aug 7, 2025Time not announced−12.0%
May 8, 2025Time not announced+2.8%
Feb 27, 2025Time not announced−2.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ZLABStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ZLAB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ZLAB

Technical Analysis

ZLAB · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 12% below its 20 day and 16% below its 50 day average. It is 2% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot at $20.73, and the nearest resistance the 200 day average at $21.44.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.0%/day
Key levels
$29.0252 week high+38.0%
$25.50Swing high (Oct 21)+21.3%
$24.3650 day average+15.8%
$23.6220 day average+12.3%
$23.45100 day average+11.5%
$21.45Pivot R1+2.0%
$21.44200 day average+1.9%
$21.03Last close
$20.73Pivot−1.4%
$20.32Pivot S1−3.4%
$19.27Swing low (Jul 14)−8.4%
$15.9652 week low−24.1%
Indicators
RSI (14)36.55Weak, oversold below 30Neutral
MACD-0.43Below its signal lineBearish
Stochastic9.0Near the bottom of its rangeOversold
ADX (14)13.6No clear trend
Williams %R-88.8Oversold below −80, overbought above −20Oversold
CCI (20)-130.4Oversold below −100, overbought above 100Oversold
Rate of change−17.5%Change over 10 sessionsBearish
ATR (14)$1.47Typical daily range, 7.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ZLAB

What happened before

See how ZLAB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ZLAB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ZLAB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ZLABHow many large options trades hit ZLAB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ZLAB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲53 buying vs 43 selling
  • ▲Shares held by funds +14.9%
  • ▲Funds holding +9
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding10394+9.6%
In funds' top 1063+100.0%
Held by funds–––
New / increased20 / 3315 / 28+23.3%
Reduced / sold out32 / 1129 / 21−14.0%
Put/call ratio0.47––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ZLAB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ZLAB Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$99K3 buys · 1 insider
Sold$11.1M33 sales · 6 insiders
83% of the selling was under pre-arranged trading plans.
2025-12 sold $336K2026-03 bought $33K2026-03 sold $4.5M2026-04 sold $918K2026-05 sold $4.1M2026-06 sold $797K2026-07 bought $33K2026-08 sold $235K2026-11 bought $33KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 10Richard GaynorDirectorBuy1,228$27.19$33K
Aug 19Yajing ChenCFOSale plan260$27.00$7K
Aug 12William LisDirectorSale plan8,506$25.00$213K
Aug 11Yajing ChenCFOSale plan619$25.00$15K
Jul 1Richard GaynorDirectorBuy1,736$19.05$33K
Jun 30Ying DuChairperson & CEOSale7,026$18.53$130K
Every insider buy and sale for ZLAB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ZLAB insider trades →

From SEC Form 4 filings by ZLAB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZLAB is in one of them and how their past ZLAB trades turned out.

ZLAB in the AI portfolios
Loading…

ZLAB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ZLAB in an article yet. Here's the latest on the wider market.

ZLAB in the news

About Zai Lab

Zai Lab is a biopharmaceutical company based in Shanghai that develops and sells prescription medicines. Its approved products treat conditions including ovarian cancer, generalized myasthenia gravis, glioblastoma, pneumonia and gastrointestinal stromal tumors. The products are sold across Greater China, where the company works with major medical centers and distributors. It also has a presence in the United States and a pipeline of additional candidates.

Headquarters
Shanghai